[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413541":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":44,"studyPopulation":44,"armGroups":48,"interventions":55,"overallOfficials":44,"centralContacts":44,"locations":61,"responsibleParty":81,"collaborators":44,"id":85,"slug":44,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":44,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":44,"enrollmentInfo":93,"targetDuration":44,"studyType":96,"phases":97,"briefSummary":98,"conditions":99,"keywords":44,"overallStatus":64,"whyStopped":44,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of server adverse events","server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.","48 hours",[14,17,19,21,24,27,30],{"measure":15,"description":15,"timeFrame":16},"Proportion of patients with modified Rankin Score 0 to 1","90 days",{"measure":18,"description":18,"timeFrame":16},"Proportion of patients with modified Rankin Score 0 to 2",{"measure":20,"description":20,"timeFrame":16},"Modified Rankin Score",{"measure":22,"description":23,"timeFrame":12},"Decrease in national institutes of health stroke scale (NIHSS)","Decrease in NIHSS scoring at 48 hours after the treatment",{"measure":25,"description":26,"timeFrame":12},"Proportion of symptomatic intracranial hemorrhage (sICH)","sICH was defined as 4 or more increase in NIHSS caused by hemorrhage",{"measure":28,"description":29,"timeFrame":12},"Proportion of intraparenchymal hemorrhage (PH1 and PH2)","Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment",{"measure":31,"description":32,"timeFrame":12},"Changes in cerebral edema","Cerebral edema was determined by cerebral volume or midline shift",[34,37],{"measure":35,"description":35,"timeFrame":36},"Differences in serum factors levels and blood gas in diverse vessel region","Hour 0",{"measure":38,"description":39,"timeFrame":40},"Changes in serum factors levels","changes in serum factors levels before and at different timepoints after recanalization","30 minutes, 24 hours",{"allocation":42,"interventionModel":43,"interventionModelDescription":44,"primaryPurpose":45,"observationalModel":44,"timePerspective":44,"maskingInfo":46},"NA","SINGLE_GROUP",null,"TREATMENT",{"masking":47,"maskingDescription":44,"whoMasked":44},"NONE",[49],{"label":50,"type":51,"description":52,"interventionNames":53},"Intra-arterial administration of 3-n-butylphthalide","EXPERIMENTAL","Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug\u002Fmin.",[54],"Drug: Intra-arterial administration of neuroprotective agents",[56],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":44},"DRUG","Intra-arterial administration of neuroprotective agents","Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug\u002Fmin",[50],[62],{"facility":63,"status":64,"city":65,"state":44,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Department of Neurology, General Hospital of Northern Theater Command","RECRUITING","Shenyang","110016","China","CN",{"type":70,"coordinates":71},"Point",[72,73],123.43278,41.79222,{"lat":73,"lon":72},[76],{"name":77,"role":78,"phone":79,"phoneExt":44,"email":80},"Hui-Sheng Chen, Ph.D.","CONTACT","+86 13352452086","chszh@aliyun.com",{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"SPONSOR_INVESTIGATOR","Hui-Sheng Chen","Director","100413541",false,"NCT04664933","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Acute ischemic stroke patients who is eligible for endovascular treatment;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\\\u003C80000\u002Fmm3);\n3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n5. Unsuitable for this clinical studies assessed by researcher.","ALL","18 Years",{"count":94,"type":95},30,"ESTIMATED","INTERVENTIONAL",[42],"To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.",[100,101,102],"Stroke, Ischemic","Intravascular Thrombosis","Mechanical Thrombectomy","2025-08-20",{"date":105,"type":106},"2025-08-21","ACTUAL",{"date":108,"type":106},"2020-12-01",{"date":110,"type":95},"2026-05-31",{"name":83,"class":6},1]